Scientific Presentations

ACCESS  LSPOR scientific presentations
 

How important is Pharmaco-economics in value based decisions - Presenter: Maher Hassoun There is an increase need to implement pharmacoeconomics/ health and this is due to many factors. Throughout the session of “overview of Pharmaco Economic Methodologies”, current challenges , importance and value of PE, cost factors relevant to Read More ...
LSPOR Intro - Introduction about ISPOR Lebanon Chapter from the annual meeting in February 2016
Outcome Research & Real World Effectiveness - Outcome Research is a critical public health tool enabling identification of public health gaps at national level, defining public health priorities, evaluating cost and measuring health outcomes. We shall take into consideration the local structure of the medical environment and standards of care, while evaluating any medical intervention benefit versus cost. This would vary from one country to another, and within the same country with different regions or institutions. Aiming for effectiveness, versus efficacy studied in clinical trial setting which in most cases would not resemble the real world situation, Real-world effectiveness data are to-date at most importance.
Overview of LSPOR Initiatives - Services/Policies-related activities, Educational activities, Research activities
Overview of Pharmaco-Economics Methodologies - Presenter: Maher Hassoun,M.S. Current Challenges Importance and value of Pharmaco Economics Types of Pharmaco Economic Analyses Executive summary and conclusion
Pharmaco-Economics Basic Principles - Presenter: Soumana Chamoun Nasser, Pharm.D. PE Basic Principles PE models and scenarios Cost definitions and Factors Steps to PE study Evaluation
Pharmacoeconomics & Outcomes Research - Dr. Rita Karam presented the MoPH outlook and perspectives regarding pharmacoeconomics and outcome research in Lebanon. After exposing ISPOR mission and objectives, she went through the overview on Lebanese health delivery and expenditure, the MOPH services, challenges, and finally MOPH Read More ...
Registry Overview - Presenter: Omar Dabbous, MD, MPH Outline Introductions Definitions Strategic rationale Design considerations Operational (implementation) considerations Examples Other issues and future considerations Conclusions
Steps in assessing the transferability of foreign CEA studies - Presenter: Silvia Evers/Professor of Public Health Technology Assessment “Generalisability is defined as the extent to which the results of a study can be generalised to the population from which the sample was drawn. Whereas, transferability is conceptualised as the extent Read More ...
Transferability of model-based economic evaluations - Presenter: Manuela Joore PhD Department of Clinical Epidemiology & Medical Technology Assessment Maastricht University Medical Center+ The Netherlands The case of trastuzumab for the adjuvant treatment of HER2-positive early breast cancer in the Netherlands Problem Evaluation resources are scarce. Is Read More ...